NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES
Division of the National Health Laboratory Service

Highlights – Week14

- In 2022 to date, 36 influenza cases have been detected from Western Cape (n=1), Kwa-Zulu Natal (n=25), Gauteng (n=1), and Mpumalanga (n=9) sentinel surveillance sites.
- An increase in number of RSV positive cases was reported from week 5 to week 13 in pneumonia surveillance. In week 13 RSV detection rate among children aged < 5 years reached high threshold and dropped to moderate level in week 14. The decrease reported in week 14 maybe due to delay in reporting.
- In 2022 to date, a total of 259 COVID-19 cases were detected from all surveillance programmes. In week 14, all programmes reported a decreasing trend in detection rate of COVID-19 cases. Of the 162 hospitalised COVID-19 cases reported with available data on outcome, 12 (7.4%) died.
- Of the 234/237 (98.7%) with variant data from SARI and ILI surveillance programmes, majority were Omicron variant (121/234, 51.7%) and variant was not assigned for 28.6% (67/234).

Programme Descriptions

Programme	Influenza-like illness (ILI)	Viral Watch	National syndromic surveillance for pneumonia
Start year	2012	1984	2009
Provinces*	KZ NW WC** MP***	EC FS GP LP MP NC NW WC	GP KZ MP NW WC
Type of site	Primary health care clinics	General practitioners	Public hospitals
Case definition	**ILI**: An acute respiratory illness with a temperature (≥38°C) and cough, & onset ≤10 days **Suspected pertussis** Any person with an acute cough illness lasting ≥14 days (or cough illness of any duration for children <1 year), without a more likely diagnosis AND one or more of the following signs or symptoms: • paroxysms of coughing, • or inspiratory "whoop", • or post-tussive vomiting • or apnoea in children <1 year; OR Any person in whom a clinician suspects pertussis **Suspected SARS-CoV-2** Any person presenting with an acute (≤14 days) respiratory tract infection or other clinical illness compatible with COVID-19[β]	**ILI**: An acute respiratory illness with a temperature (≥38°C) and cough, & onset ≤10 days **Suspected SARS-CoV-2** Any person presenting with an acute (≤14 days) respiratory tract infection or other clinical illness compatible with COVID-19[β]	**SRI**: Acute (symptom onset≤10 days) or chronic (symptom onset >10) lower respiratory tract infection **Suspected pertussis** Any person with an acute cough illness lasting ≥14 days (or cough illness of any duration for children <1 year), without a more likely diagnosis AND one or more of the following signs or symptoms: • paroxysms of coughing, • or inspiratory "whoop", • or post-tussive vomiting • or apnoea in children <1 year; OR Any person in whom a clinician suspects pertussis. **Suspected SARS-CoV-2** Any person admitted with a physician-diagnosis of suspected COVID-19 and not meeting SRI case definition.
Specimens collected	Oropharyngeal & nasopharyngeal swabs	Throat and/or nasal swabs or Nasopharyngeal swabs	Oropharyngeal & nasopharyngeal swabs
Main pathogens tested**	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2
Testing Methods	**INF and RSV** - Fast-Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al*., *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay (Corman *et al*., *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)	**INF and RSV** - Fast-Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al*., *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay Corman *et al*., *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)	**INF and RSV** - Fast Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al*., *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay (Corman *et al*., *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)

Epidemic Threshold

Thresholds are calculated using the Moving Epidemic Method (MEM), a sequential analysis using the R Language, available from: http://CRAN.R-project.org/web/package=mem) designed to calculate the duration, start and end of the annual influenza epidemic. MEM uses the 40th, 90th and 97.5th percentiles established from available years of historical data to calculate thresholds of activity. Thresholds of activity for influenza and RSV are defined as follows: Below seasonal threshold, Low activity, Moderate activity, High activity, Very high activity. For influenza, thresholds from outpatient influenza like illness (ILI in primary health care clinics) are used as an indicator of disease transmission in the community and thresholds from pneumonia surveillance are used as an indicator of impact of disease. For RSV, thresholds from pneumonia surveillance, using data from children aged < 5 years are used to define the start and end of the season.

* EC: Eastern Cape; FS: Free State; GP: Gauteng; KZ: KwaZulu-Natal; LP: Limpopo; MP: Mpumalanga: NC: Northern Cape; NW: North West; WC: Western Cape
**Started in 2019
***Started in November 2020
****INF: influenza virus; RSV: respiratory syncytial virus; BP: *Bordetella pertussis*; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
[β]Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhoea). Testing for SARS-CoV-2 was initiated in all three surveillance programmes in week 10 of 2020 (week starting 2 March 2020).

Comments:

Influenza

In 2022 to date, a total of 36 influenza cases have been reported. In week 14, transmission and impact were below threshold.

ILI programme: In 2022 to date, specimens from 426 patients meeting ILI case definition were tested from five ILI sites. Influenza was detected in 14 (3.3%) patients, 11 (78.6%) were influenza A(H1N1)pdm09 and 4 (28.6%) were pending influenza subtype results. (Fig1, Table1).

Viral Watch programme: In 2022 to date, specimens from 57 patients from four of the 8 provinces participating in Viral Watch surveillance were tested. Influenza was detected in 1/57 (1.8%) patient from Gauteng Province. (Fig7, Table5)

Pneumonia surveillance: Since the beginning of 2022, specimens from 1 698 patients with SRI were tested from the 6 sentinel sites. Influenza was detected in 22 (1.3%) patients, 14/22 (63.6%) were influenza A(H1N1)pdm09, and 2/22 (9.1) were influenza A (H3N2). (Fig12, Table9)

In addition, 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions were tested for influenza. Two (6.3%) tested positive with influenza B(Victoria) and AH1N1 (pdm09).

Respiratory syncytial virus

RSV activity increased above seasonal threshold in week 7 (week starting 14 February), reached high threshold levels in week 13 and dropped to moderate level in week 14 among children aged <5 years in pneumonia surveillance.

ILI programme: In 2022 to date, 426 specimens from patients meeting the ILI case definition were tested and RSV was detected in 43 (10.1%) patients. Of which, 38 (88.4%) were RSV subgroup A, one (2.3%) RSV subgroup B, two (4.7%) RSV subgroup inconclusive and RSV subgroup results were pending for two (4.7%). (Fig4, Table2)

Viral Watch programme: In 2022 to date, 57 specimens from Viral Watch patients were tested and RSV was detected in 2/57 (3.5%). (Fig9, Table6)

Pneumonia surveillance: Since the beginning of 2022, 1 698 specimens were tested and RSV was detected in specimens of 287 (16.9%) patients. Of which, 93 (32.4%) were RSV subgroup A, 148 (51.6%) were RSV subgroup B and RSV subgroup results were pending for 41 (14.3%) (Fig14, Table10).

In addition, 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions were tested for RSV and none tested positive for RSV.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)

ILI programme: From 3 January 2022 to date, 426 patients were tested and SARS-CoV-2 was detected in 57 (13.4%) patients. Of the 41 (41/57, 71.9%) with variant data, most common variant was Omicron (17/41, 41.5%) and for 39.0% (16/41) variant was not assigned. (Fig6, Table4)

Viral Watch programme: From 3 January 2022 to date, 57 patients presenting with ILI were tested and SARS-CoV-2 was detected in 21 (36.8%). The majority of SARS-CoV-2 cases were Omicron variant 14/21 (66.7%), 4 unassigned for variant and 3 were pending results. (Fig11, Table8)

Pneumonia surveillance: From 3 January 2022 to date, 1 697 patients with severe respiratory illness (SRI) were tested and SARS-CoV-2 was detected in 169 (10.0%) patients. Of the 145 (145/169, 85.8%) with variant data, majority were Omicron variant 69.7% (101/145), Alpha and Delta contributed 0.7% (1/145) each and variant was not assigned for 29.0% (42/145). (Fig17, Table12)

In addition, SARS-CoV-2 was detected in 12 of 32 (37.5%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions. Of the 10 (10/12, 83.3%) with variant data, 80.0%% (8/10) were Omicron variant and variant was not assigned for 20% (2/10).



Figure 1. Number of influenza positive cases* by influenza subtype and lineage and detection rate*** by week, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022**

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces
***Only reported for weeks with >10 specimens submitted
Inconclusive: insufficient viral load in sample and unable to characterise further
**Influenza was detected in two (10.0%) of 20 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition and it was influenza B(Victoria) and A H1N1(pdm09). These are not included in the epidemiological curve.

Table 1. Number of laboratory confirmed influenza cases by subtype and lineage and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 11/04/2022**

Clinic (Province)	A(H1N1)pdm09	A(H3N2)	A subtype inconclusive	A subtype pending results[β]	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results[β]	Total samples
Agincourt (MP)	3	0	0	0	0	0	0	0	75
Eastridge (WC)	0	0	0	0	0	0	0	0	75
Edendale Gateway (KZ)	10	0	0	1	0	0	0	0	133
Jouberton (NW)	0	0	0	0	0	0	0	0	123
Mitchell's Plain (WC)	0	0	0	0	0	0	0	0	20
Total:	13	0	0	1	0	0	0	0	426

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga
Inconclusive: insufficient viral load in sample and unable to characterise further
[β]influenza A subtype or B lineage results are pending

****Influenza was detected in two (10.0%) of 20 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition, one influenza B(Victoria) and one influenza A H1N1(pdm09). These are not included in the table.



Figure 2. Influenza percentage detections and epidemic thresholds* among cases of all ages, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022

*Thresholds based on 2012-2019 data

Data are provisional as reported to date (Data for this report drawn on (12/04/2022). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection. Data cleaning is ongoing and this may result in some changes in subsequent reports.



Figure 3. Number of patients testing positive for respiratory syncytial virus* by province and detection rate by week, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022

*RSV was not detected from 20 specimens of patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition.

Data are provisional as reported to date (Data for this report drawn on (12/04/2022). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection. Data cleaning is ongoing and this may result in some changes in subsequent reports.



Figure 4. Number of patients testing positive for respiratory syncytial virus* by subgroup and detection rate by week, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022

Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified.
*RSV was not detected from 20 specimens of patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 2. Number of patients testing positive for respiratory syncytial virus (RSV) by subgroups identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022**

Clinic (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Agincourt (MP)	13	0	0	0	0	75
Eastridge (WC)	0	1	0	0	1	75
Edendale Gateway (KZ)	25	0	0	2	1	133
Jouberton (NW)	0	0	0	0	0	123
Mitchell's Plain (WC)	0	0	0	0	0	20
Total	38	1	0	2	2	426

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga
Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
*RSV results for subgroups are pending
**RSV was not detected from 20 specimens of patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.



Figure 5. Number of patients testing positive for SARS-CoV-2* by province and detection rate by week, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces
*SARS-CoV-2 was detected in 5 of 20 (25%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 3. Number of patients positive for SARS-CoV-2* identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 03/01/2022 – 10/04/2022

Clinic (Province)	SARS-CoV-2 positive	Total samples tested
Agincourt (MP)	23	75
Eastridge (WC)	3	75
Edendale Gateway (KZ)	5	133
Jouberton (NW)	22	123
Mitchell's Plain (WC)	4	20
Total:	57	426

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga
*SARS-CoV-2 was detected in 5 of 20 (25%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.



Figure 6. Number and detection rate of laboratory confirmed SARS-CoV-2* cases by variant type (variant PCR/sequencing) and week, Influenza-like illness (ILI) surveillance in primary health care clinics, 03/01/2022 – 10/04/2022

*Specimens are from patients with influenza-like illness at 5 sentinel sites in 4 provinces who met suspected SARS-CoV-2 case definition or met ILI case definition

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Table 4. Number of SARS-CoV-2* positive cases by variant (variant PCR and/or sequencing) identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 03/01/2022 – 10/04/2022

Clinic (Province)	Non-Alpha/Beta/Delta	Alpha (20I)	Beta (20H)	Delta (21A, 21I, 21J)	C.1.2 (20D)	Omicron (21K, 21L, 21M)	Pending	Unable to assign	Total SARS-CoV-2 positive
Agincourt (MP)	0	0	0	0	0	5	7	11	23
Eastridge (WC)	0	0	0	0	0	2	1	0	3
Edendale Gateway (KZ)	0	0	0	0	0	3	3	0	6
Jouberton (NW)	0	0	0	0	0	5	4	12	21
Mitchell's Plain (WC)	0	0	0	0	0	2	1	1	4
Total:	0	0	0	0	0	17	16	24	57

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga
*Specimens are from patients with influenza-like illness at 5 sentinel sites in 4 provinces who met suspected SARS-CoV-2 case definition or met ILI case definition

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results



Figure 7. Number of positive patients* by influenza subtype and lineage and detection rate by week, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022**

*Specimens from patients with Influenza-like illnesses at 90 sentinel sites in 8 provinces
** Only reported for weeks with >10 specimens submitted.
Inconclusive: insufficient viral load in sample and unable to characterise further

Table 5. Number of laboratory confirmed influenza cases by influenza subtype and lineage and total number of samples tested by province, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	A subtype pending results*	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results*	Total samples
Eastern Cape	0	0	0	0	0	0	0	0	2
Free State	0	0	0	0	0	0	0	0	0
Gauteng	0	1	0	0	0	0	0	0	35
Limpopo	0	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0	0	0	0
North West	0	0	0	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0	0	0	0
Western Cape	0	0	0	0	0	0	0	0	18
Total:	0	1	0	0	0	0	0	0	57

Inconclusive: insufficient viral load in sample and unable to characterise further
*Influenza A subtype or B lineage results are pending



Figure 8. Number of RSV positive cases testing positive for respiratory syncytial virus (RSV)* by subgroup and detection rate by week, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022**

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces
** Only reported for weeks with >10 specimens submitted.

Table 6. Number of RSV positive cases identified and total number of samples tested by province, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022

Province	RSV A	RSV B	RSV AB	RSV subgroup inconclusive	RSV subgroup pending results*	Total samples tested
Eastern Cape	0	0	0	0	0	2
Free State	0	0	0	0	0	0
Gauteng	1	0	0	0	0	35
Limpopo	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0
North West	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0
Western Cape	0	1	0	0	0	18
Total:	1	1	0	0	0	57

*RSV results for subgroups are pending
**Inconclusive: insufficient viral load in sample and unable to characterise further



Figure 9. Number of patients testing positive for SARS-CoV-2*, by site and detection rate by week, ILI surveillance - Viral Watch, 03/01/2022 – 11/04/2022**

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces
** Only reported for weeks with >10 specimens submitted.

Table 7. Number of SARS-CoV-2 positive cases identified and total number tested by province, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022

Province	SARS-CoV-2 positive	Total samples tested
Eastern Cape	1	2
Free State	0	0
Gauteng	14	35
Limpopo	0	0
Mpumalanga	0	0
North West	0	2
Northern Cape	0	0
Western Cape	6	18
Total:	21	57



Figure 10. Number and detection rate of laboratory confirmed SARS-CoV-2* cases by variant type (variant PCR/sequencing) and week, ILI surveillance - Viral Watch, 03/01/2022 – 10/04/2022

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Table 8. Number of SARS-CoV-2* positive cases by variant (variant PCR and/or sequencing) identified and total number of samples tested by province, ILI surveillance - Viral Watch, 03/01/2022 – 11/04/2022

Clinic (Province)	Non-Alpha/Beta/Delta	Alpha (20I)	Beta (20H)	Delta (21A, 21I, 21J)	C.1.2 (20D)	Omicron (21K, 21L, 21M)	Pending	Unable to assign	Total SARS-CoV-2 positive
Eastern Cape	0	0	0	0	0	1	0	0	1
Free State	0	0	0	0	0	0	0	0	0
Gauteng	0	0	0	0	0	8	1	4	13
Limpopo	0	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0	0	0	0
North West	0	0	0	0	0	0	0	0	0
Northern Cape	0	0	0	0	0	0	0	0	0
Western Cape	0	0	0	0	0	5	1	0	6
Total:	0	0	0	0	0	14	2	4	20

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results



Figure 11. Number of positive influenza positive cases* by influenza subtype and lineage and detection rate*** by week, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022**

Inconclusive: insufficient viral load in sample and unable to characterise further
*Specimens from patients hospitalised with pneumonia at 7 sentinel sites in 5 provinces
***Only reported for weeks with >10 specimens submitted
**Influenza was not detected in 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 9. Number of laboratory confirmed influenza cases by subtype and lineage* and total number of samples tested by hospital, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

Hospital (Province)	A(H1N1)pdm09	A(H3N2)	A subtype inconclusive	A subtype pending results***	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results***	Total samples
Edendale (KZ)	9	0	0	5	0	0	0	0	341
Helen Joseph-Rahima Moosa (GP)	0	1	0	0	0	0	0	0	464
Klerksdorp-Tshepong(NW)	0	0	0	0	0	0	0	0	141
Mapulaneng-Matikwana (MP)	1	0	0	1	0	0	0	0	151
Red Cross (WC)	0	0	0	0	0	0	0	0	299
Mitchell's Plain (WC)	1	0	0	0	0	0	0	0	188
Tembisa (GP)	0	0	0	0	0	0	0	0	25
Tintswalo (MP)	3	1	0	0	0	0	0	0	89
Total:	14	2	0	6	0	0	0	0	1 698

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape
Inconclusive: insufficient viral load in sample and unable to characterise further
***influenza A subtype or B lineage results are pending

*Influenza was not detected in 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.



Figure 12. Influenza percentage detections and epidemic thresholds* among cases of all ages, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

*Thresholds based on 2010-2019 data



Figure 13. Number of patients testing positive for respiratory syncytial virus* by province and detection rate by week, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

*RSV was not detected in 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition.

Data are provisional as reported to date (Data for this report drawn on (12/04/2022). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection. Data cleaning is ongoing and this may result in some changes in subsequent reports.



Figure 14. Number of patients testing positive for respiratory syncytial virus* by subgroup and detection rate by week, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
RSV subgroup pending: RSV results for subgroups are pending
*RSV was not detected in 32 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 10. Number of patients positive for respiratory syncytial virus subgroups by subgroups identified and total number of samples tested by hospital, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022**

Hospital (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Edendale (KZ)	63	1	0	2	10	341
Helen Joseph-Rahima Moosa (GP)	12	95	1	0	14	464
Klerksdorp-Tshepong(NW)	0	2	0	0	6	141
Mapulaneng-Matikwana (MP)	4	2	0	0	0	151
Red Cross (WC)	11	29	0	0	10	299
Mitchell's Plain (WC)	1	14	0	0	1	188
Tembisa (GP)	0	1	0	0	0	25
Tintswalo (MP)	2	4	0	2	0	89
Total:	93	148	1	4	41	1 698

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape
Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
*RSV results for subgroups are pending

**RSV was not detected in 16 specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.



Figure 15. RSV percentage detections and epidemic thresholds* among children aged < 5 years, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

*Thresholds based on 2010-2019 data

Data are provisional as reported to date (Data for this report drawn on (12/04/2022). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection. Data cleaning is ongoing and this may result in some changes in subsequent reports.



Figure 16. Number of patients testing positive for SARS-CoV-2* by province and detection rate by week, pneumonia surveillance public hospitals, 03/01/2022 –10/04/2022

*Specimens from patients hospitalized with pneumonia at 6 sentinel sites in 5 provinces
*SARS-CoV-2 was detected in 12 of 32 (37.5%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 11. Number of patients positive for SARS-CoV-2* and total number of samples tested by hospital, pneumonia surveillance public hospitals, 03/01/2022 –10/04/2022

Hospital (Province)	SARS-CoV-2 positive	Total samples tested
Edendale (KZ)	50	341
Helen Joseph-Rahima Moosa (GP)	24	463
Klerksdorp-Tshepong(NW)	24	141
Mapulaneng-Matikwana (MP)	23	151
Red Cross (WC)	14	299
Mitchell's Plain (WC)	22	188
Tembisa** (GP)	1	25
Tintswalo (MP)	11	89
Total:	169	1 697

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape** Tembisa Hospital started enrolling on 14 March 2022
*SARS-CoV-2 was detected in 12 of 32 (37.5%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.



Figure 17. Number and detection rate of laboratory confirmed SARS-CoV-2 cases* by variant type (variant PCR/sequencing), pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

*Specimens are from hospitalized patients at 7 sentinel sites in 5 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition
Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Table 12. Number of SARS-CoV-2 positive cases* by variant (variant PCR and/or sequencing) identified and total number of samples tested by hospital, pneumonia surveillance public hospitals, 03/01/2022 – 10/04/2022

Hospital (Province)	Non-Alpha/Beta/Delta	Alpha (20I)	Beta (20H)	Delta (21A, 21I, 21J)	C.1.2 (20D)	Omicron (21K, 21L, 21M)	Pending	Unable to assign	SARS-CoV-2 positive
Edendale (KZ)	0	0	0	1	0	37	8	9	55
Helen Joseph-Rahima Moosa (GP)	0	1	0	0	0	12	6	5	24
Klerksdorp-Tshepong(NW)	0	0	0	0	0	13	6	5	24
Mapulaneng-Matikwana (MP)	0	0	0	0	0	11	5	9	25
Red Cross (WC)	0	0	0	0	0	8	2	4	14
Mitchell's Plain (WC)	0	0	0	0	0	12	3	7	22
Tembisa (GP)	0	0	0	0	0	1	0	0	1
Tintswalo (MP)	0	0	0	0	0	7	1	3	11
Total:	0	1	0	1	0	101	31	42	176

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape
*Specimens are from hospitalized patients at 7 sentinel sites in 5 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Data are provisional as reported to date (Data for this report drawn on (12/04/2022). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection. Data cleaning is ongoing and this may result in some changes in subsequent reports.

Table13: Characteristics of individuals with laboratory-confirmed SARS-CoV-2, enrolled in influenza-like illness (ILI) and pneumonia surveillance programmes, South Africa, 3 January 2022 – 10 April 2022

Characteristic	Influenza–like illness (ILI), public-sector, n=62 (%)	Pneumonia, n=176 (%)
Age group (years)		
0-9	12/62 (19.4)	41/176 (23.3)
10-19	9/62 (14.5)	5/176 (2.8)
20-39	14/62 (22.6)	50/176 (28.4)
40-59	20/62 (32.3)	45/176 (25.6)
60-79	6/62 (9.7)	29/176 (16.5)
≥80	1/62 (1.6)	6/176 (3.4)
Sex-female		
	36/62 (58.1)	96/176 (54.6)
Province*		
Gauteng	N/A	25/176 (14.2)
KwaZulu-Natal	7/62 (11.3)	55/176 (31.3)
Mpumalanga	25/62 (40.3)	36/176 (20.5)
North West	23/62 (37.1)	24/176 (13.6)
Western Cape	7/62 (11.3)	36/176 (20.5)
Race		
Black	45/62 (72.6)	147/176 (83.5)
Coloured	8/62 (13.1)	26/176 (14.8)
Asian/Indian	0/62 (0.0)	0/176 (0.0)
White	9/62 (14.5)	1/176 (0.6)
Other	0/62 (0.0)	2/176 (0.6)
Variant		
Non-Alpha/Beta/Delta	0/62 (0.0)	0/176 (0.0)
Alpha(20I)	0/62 (0.0)	1/176 (0.6)
Beta(20H)	0/62 (0.0)	0/176 (0.0)
Delta(21A, 21I, 21J)	0/62 (0.0)	1/176 (0.6)
C.1.2(20D)	0/62 (0.0)	0/176 (0.0)
Omicron(21K,21L,21M)	20/62 (32.3)	101/176 (57.4)
Pending results[$]	17/62 (27.4)	31/176 (17.6)
Unable to assign[$$]	25/62 (28.1)	42/176 (23.9)
Presentation		
Fever	45/62 (72.6)	72/175 (41.1)
Cough	61/62 (98.4)	155/175 (89.1)
Shortness of breath	26/62 (41.9)	106/175 (60.6)
Chest pain	25/62 (40.3)	72/175 (41.1)
Diarrhoea	7/62 (11.3)	21/175 (12.0)
Underlying conditions		
Hypertension	12/62 (19.7)	30/175 (17.0)
Cardiac	1/62 (1.6)	4/175 (2.3)
Lung disease	0/62 (0.0)	1/175 (0.6)
Diabetes	2/62 (3.2)	17/175 (9.7)
Cancer	0/62 (0.0)	3/175 (1.7)
Tuberculosis	0/62 (0.0)	17/175 (9.7)
HIV-infection	9/62 (14.5)	66/175 (37.7)
Other **	1/62 (1.6)	2/175 (1.2)
SARS-CoV-2 Vaccine**		
Pfizer-BioNTech (1st dose)	12/22 (54.5)	29/38 (76.3)
Pfizer-BioNTech (2nd dose)	10/22 (45.5)	22/38 (57.9)
Johnson & Johnson	8/22 (36.4)	20/38 (52.6)
Booster	0/22 (0.0)	2/38 (5.3)
Unknown	2/22 (9.1)	
Management		
Oxygen therapy	0/62 (0.0)	90/175 (51.4)
ICU admission	N/A	0/175 (0.0)
Ventilation	N/A	2/175 (1.1)
Outcome***		
Died	0/62 (0.0)	12/162 (7.4)

*ILI surveillance not conducted in Gauteng province

**Chronic lung, liver and kidney disease, organ transplant, pregnancy, malnutrition, obesity, tracheostomy, prematurity, seizure, stroke, anaemia, asplenia, burns, Systemic lupus erythematosus, seizures

***Outcome includes patients who are still hospitalised, have been discharged or referred, and those who died

[$] Pending results: outstanding variant results

[$$] Unable to assign: no lineage assigned due to poor- sequence quality OR low viral load (ct=>35) OR variant PCR could not assign variant and no sequencing result

****Includes only cases who are vaccinated against SARS-COV-2

Note: Children may be over-represented amongst hospitalised patients due to the inclusion of a large paediatric hospital in Cape Town.
Of the 12 patients who died, the 20-39-year, 40-59-year, and ≥60-year age groups reported contributed equaly 4 (33.3%) each; 7/12 (58.3) were female.

Methods

SARS-CoV-2 Testing

March 2020 – March 2021: SARS-CoV-2 was detected using the Roche E gene real-time PCR assay (Corman et al. *Euro Surveillance* 2020) with cycle threshold (C_t) <40 interpreted as positive for SARS-CoV-2. From April 2021 to date the laboratory changed to the Allplex™ SARS-CoV-2/FluA/FluB/RSV kit (Seegene Inc., Seoul, South Korea), with positivity assigned if the PCR cycle threshold (C_t) was <40 for ≥1 gene targets (N, S or RdRp).

A confirmed SARS-CoV-2 case is a person of any age enrolled in surveillance with laboratory confirmation of SARS-CoV-2 infection by PCR. Only positive SARS-CoV-2 specimens on PCR are further tested to determine variant/lineage type by variant PCR or genomic sequencing.

Variant PCR

Allplex™ SARS-CoV-2 Variants I PCR detects Alpha and Beta/Gamma variants. The assay was conducted on all SARS-CoV-2-positive samples from 1 March 2020 – 30 June 2021.

Allplex™ SARS-CoV-2 Variants II PCR detects Delta variant and distinguishes Beta from Gamma. The assay was conducted on SARS-CoV-2-positive samples from 1 Jan to 30 June 2021.

Extraction: Total nucleic acids were extracted from 200µl NP/OP samples in universal or viral transport medium using a MagNA Pure 96 automated extractor and DNA/Viral NA Small Volume v2.0 extraction kit (Roche Diagnostics, Mannheim, Germany).

SARS-CoV-2 genomic surveillance

SARS-CoV-2 Whole-Genome Sequencing and Genome Assembly

RNA Extraction

RNA was extracted either manually or automatically in batches, using the QIAamp viral RNA mini kit (QIAGEN, CA, USA) or the Chemagic 360 using the CMG-1049 kit (PerkinElmer, MA, USA). A modification was done on the manual extractions by adding 280 µl per sample, in order to increase yields. 300 µl of each sample was used for automated magnetic bead-based extraction using the Chemagic 360. RNA was eluted in 60 µl of the elution buffer. Isolated RNA was stored at -80 °C prior to use.

PCR and Library Preparation

Sequencing was performed using the Illumina COVIDSeq protocol (Illumina Inc., CA, USA) or nCoV-2019 ARTIC network sequencing protocol v3 (https://artic.network/ncov-2019). These are amplicon-based next-generation sequencing approaches. Briefly, for the nCoV-2019 ARTIC network sequencing protocol, the first strand synthesis was carried out on extracted RNA samples using random hexamer primers from the SuperScript IV reverse transcriptase synthesis kit (Life Technologies, CA, USA) or LunaScript RT SuperMix Kit (New England Biolabs (NEB), MA , USA). The synthesized cDNA was amplified using multiplex polymerase chain reactions (PCRs) using ARTIC nCoV-2019 v3 primers. For the COVIDSeq protocol, the first strand synthesis was carried out using random hexamer primers from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions.

For Illumina sequencing using the nCoV-2019 ARTIC network sequencing protocol, the pooled PCR products underwent bead-based tagmentation using the Nextera Flex DNA library preparation kit (Illumina Inc., CA, USA). The adapter-tagged amplicons were cleaned up using AmpureXP purification beads (Beckman Coulter, High Wycombe, UK) and amplified using one round of PCR. The PCRs were indexed using the Nextera CD indexes (Illumina Inc., CA, USA) according to the manufacturer's instructions. For COVIDSeq sequencing protocol, pooled PCR amplified products were processed for tagmentation and adapter ligation using IDT for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed as per protocols provided by the manufacturer (Illumina Inc., CA, USA). Pooled samples from both COVIDSeq protocol and nCoV-2019 ARTIC network protocol were quantified using Qubit 3.0 or 4.0 fluorometer (Invitrogen Inc., MA, USA) using the Qubit dsDNA High Sensitivity assay according to manufacturer's instructions. The fragment sizes were analyzed using TapeStation 4200 (Invitrogen Inc., MA, USA). The pooled libraries were further normalized to 4nM concentration and 25 µl of each normalized pool containing unique index adapter sets were combined in a new tube. The final library pool was denatured and neutralized with 0.2 N sodium hydroxide and 200 mM Tris-HCL (pH7), respectively. 1.5 pM sample library was spiked with 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput Kit v2 and run on the Illumina NextSeq 550 instrument (Illumina Inc., CA, USA).

Assembly, Processing and Quality Control of Genomic Sequences

Raw reads from Illumina sequencing were assembled using the Exatype NGS SARS-CoV-2 pipeline v1.6.1, (https://sars-cov-2.exatype.com/). The resulting consensus sequence was further manually polished by considering and correcting indels in homopolymer regions that break the open reading frame (probably sequencing errors) using Aliview v1.27, (http://ormbunkar.se/aliview/) (Larsson, 2014). Mutations resulting in mid-gene stop codons and frameshifts were reverted to wild type. All assemblies determined to have acceptable quality (defined as having at least 1 000 000 reads and at least 40 % 10 X coverage) were deposited on GISAID (https://www.gisaid.org/) (Elbe & Buckland-Merrett, 2017; Shu & McCauley, 2017).

Classification of Lineage, Clade and Associated Mutations

Assembled genomes were assigned lineages using the 'Phylogenetic Assignment of Named Global Outbreak Lineages' (PANGOLIN) software suite (https://github.com/hCoV-2019/pangolin) (Rambaut et al., 2020), a tool used for dynamic SARS-CoV-2 lineage classification. The SARS-CoV-2 genomes in our dataset were also classified using the clade classification proposed by NextStrain (https://nextstrain.org/), a tool built for real-time tracking of the pathogen evolution (Hadfield et al., 2018).